Children's Mercy Hospital | Type 1 Diabetes TrialNet

https://www.childrensmercy.org/pediatric-endocrinology-and-diabetes/

2401 Gillham Road

Endocrine/Diabetes Office

Kansas City, MO 64108

United States

Children's Mercy Hospital is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Wayne Moore, MD, PhD the TrialNet team at Children's Mercy is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators

Wayne

Moore

MD, PhD

Dr. Moore is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications at a translational and clinical level. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Moore has been at Children’s Mercy Hospital for over 20 years and was at University of Kansas Medical Center prior to Children’s Mercy. MD, PhD and Pediatric Residency were completed at University of Minnesota.

Mark

Clements

MD, PhD

Dr. Clements is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications, and the use of big data predictive analytics to improve diabetes care. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Clements has been at Children’s Mercy Hospital for 13 years. He attended Butler University, then trained in the Medical Scientist Training Program (MD/PhD program) at Washington University in St Louis. He completed his Pediatric Residency and Endocrine/Diabetes Fellowship at Children’s Mercy Kansas City..

Fadi

Al Muhaisen-Saenz

MD, FAAP

Fadi Al Muhaisen, MD, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Endocrine Disorders in Cancer patients clinic. He has a joint appointment at the Kansas University-Wichita School of Medicine as a Clinical Assistant Professor. His expertise is in the use of clinical and research to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes. His role in the Clinical Center is recruiting and assisting in prevention trials. Dr. Al Muhaisen is a member of the American Academy of Pediatrics, board certified, and a member of Pediatric Endocrine Society

Ryan

McDonough

DO, FAAP

Ryan McDonough, DO, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Children’s Diabetes Center. His expertise is in the use of clinical and medical informatics to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes. His role in the Clinical Center is recruiting and assisting in prevention trials. He completed his medical school at Des Moines University in Des Moines, IA, and Pediatrics Residency and Pediatric Endocrinology & Diabetes Fellowship at Children’s Mercy.

Research Coordinators

Darlene

Brenson-Hughes

Clinical Trials Coordinator II, CCRC

Darlene Brenson-Hughes is the Lead Coordinator for the TrialNet Clinical Center at Children’s Mercy Kansas City. She is responsible for oversight of all aspects of the Pathway to Prevention Program, including screening and monitoring, support of affiliate sites, and engagement with referring clinicians. She has been with Children’s Mercy since 2008.

Laura

Williams

Clinical Research Coordinator

Laura Williams, MS, is a Clinical Research Coordinator at Children's Mercy Hospital - Kansas City. She is responsible for the recruiting and enrolling for TN01 at our Broadway Clinic. She has been with Children's Mercy since early 2018.

Jennifer

James

Jennifer James is a clinical research coordinator for Children's Mercy Kansas City. She is mainly responsible for the screenings and enrollment for TN01 at our College Boulevard location. She has been with Children's Mercy since 2012.

Aliza

Elrod

Aliza Elrod is a Research Database Coordinator at Children’s Mercy Hospital - Kansas City. She is responsible for quality assurance of all TN01 visits primarily making sure all source documents and consent forms are filled out completely and accurately as well as making sure the eCRF’s are entered in the TN01’s website completely and accurately. She has been with Children’s Mercy since 1996.

Lacey

Deardoff

CCRC, MBA-HCA

Clinical Trials Coordinator

Lacey Deardoff is a Clinical Trials Coordinator for Children’s Mercy Kansas City. She is responsible for assisting with screenings and enrollment for TN01 at various locations. She is also a Lead Coordinator on one of TrialNet’s prevention studies. She has been with Children’s Mercy since 2017 with a Master’s degree in Business Administration.

Susan

Mitchell

RN, BSN

Clinical Research Coordinator

Susan is a Clinical Research Coordinator at Children’s Mercy Wichita Specialty Clinics in Wichita, Kansas. She is responsible for the screening and enrollment visits for TN01 in the Wichita area and also outreach to Western Kansas. She is new to research and has been with Children’s Mercy since 2017.

Jessica L.

Slover

BS, CCRC, ACRP-PM

Clinical Trials Coordinator

Jessica Slover-Dorsey is a Clinical Trials Coordinator for Children’s Mercy in Kansas City. She is responsible for assisting with screening and enrollment for TN01 at all of the CMH Kansas City locations. She has been with Children’s Mercy since April, 2017. She has a certification in Clinical Trial Coordination and Project Management and a Bachelor’s of Science in Healthcare Administration Management.

Dara

Watkins

MA, CCRP

Research Associate

Dara Watkins is a Research Associate for Children's Mercy Kansas City. She is responsible for the screenings and enrollment for TN01 at either our Broadway or North locations. She has been with Children's Mercy since 2011.

Casey

McClain

BPS, MHA, CCRC

Clinical Trials Team Manager

Casey McClain is the Clinical Trials Team Manager for the Endocrinology Division. She has recently joined the Endocrine Team at Children’s Mercy with over ten years of experience in Clinical Trial Management. Casey is responsible for the providing management of clinical research operations, including quality management, personnel management, and regulatory compliance within the Endocrinology Division. Casey has a Business Degree from Rockhurst University and a Masters in Healthcare Administration from Park University. She has been at Children’s Mercy since 2008.

Barb

Seuferling

Clinical Research RN Coordinator

Barb Seuferling, RN, is a Clinical Research RN Coordinator at Children’s Mercy in Kansas City. She is responsible for monitoring visits and assisting with eligibility visits for TN01. She is also assisting with several TrialNet prevention trials being conducted at Children’s Mercy. She is new to the Endocrine Research group but has been a critical care inpatient/clinic nurse since 2013 and has been with Children’s Mercy since 2016.

Steve

Orlich

RN, ACRP-CP

Clinical Research RN Coordinator

Steve Orlich is a Clinical Research RN Coordinator at Children’s Mercy Kansas City. He has over 20 years’ experience as a Nurse working in Pediatrics, Trauma, Post Anesthesia Care, and Research. He joined the Endocrinology Research team in late 2017. He has a combined 10 year background as both a Clinical Nurse Educator in early phase human research and as a Clinical Research Associate. He has experience with clinical research staff training and development and Good Clinical Practices (GCP). He has performed monitoring for all phases of multicenter human research trials. He has conducted site selection, initiation, monitoring, drug accountability, and close out visits. He is currently responsible for TN01 screening, enrollment, and monitoring visits. He also assists with all TrialNet prevention studies conducted at Children’s Mercy.

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with Children's Mercy to offer convenient participation in our research programs

Columbia

University of Missouri
CRC-N508 Health Science #1, Hospital Dr, Columbia, MO 65212

Kansas City

Truman Medical Center
2411 Holmes St, SOM M4-329, Kansas City, MO 64108

Kansas City

KU Diabetes Institute - University of Kansas Medical Center
3901 Rainbow Blvd. MS 1064, Kansas City, KS 33160

Omaha

University of Nebraska Medical Center
985456 Nebraska Medical Center, Omaha, NE 68198
402.559.1193

Topeka

Cotton-O'Neil Clinical Research Center
3520 SW 6th Avenue, Topeka, KS 66606

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.

Prevention Study

Abatacept

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.

Teplizumab (Closed to Enrollment-Study Ongoing)

We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.

Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.

Longterm

Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.